NK-1 Drug Fills Motion Sickness Gap - Top-Institutions - MDSpire

NK-1 Drug Fills Motion Sickness Gap

Tradipitant demonstrates 50% to 70% risk reduction for vomiting incidence during motion exposure in phase 3 trials.

  • By

  • Kerri Miller

  • January 2, 2026

  • 3 min

Share

Top Institutions in Otolaryngology

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neuropharmacology
    • Gastroenterology
    • Clinical Trials

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurology
    • Gastroenterology
    • Clinical Pharmacology

  • #3

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Neuroscience
    • Pharmacology
    • Clinical Research

  • #4

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neuropharmacology
    • Clinical Trials
    • Gastroenterology

Original Source(s)

NK-1 Drug Fills Motion Sickness Gap

  • by Kerri Miller

  • January 2, 2026

Related Content

Chronic Back Pain Tied to Auditory Hypersensitivity

Pain reprocessing therapy produced small but measurable reductions in cross-modal sensory amplification, pointing to a broader neurological signature of chronic back pain than previously recognized.

Medical Oddities: Essential Oil, Deadly Consequences

A cabinet mix-up, a chatty heart, a violet catheter bag, stressed kids, and tea that won’t save the brain—just another week.

Medical Oddities: For the Birds—and the Brain

Birds for brains, blackout laughs, anti-aging tea, thin air, muscle memory—and torn marriages, all with a clinical touch this week.